Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

L Alexis Hoeferlin; Charles E Chalfant; Margaret A Park

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

J Surg Sci. 2013 Dec;1(1):3-7.

Authors

L Alexis Hoeferlin¹, Charles E Chalfant¹, Margaret A Park¹

Affiliation

¹ Hunter Holmes McGuire VAMC, Dept. of Research and Development, Richmond VA, 23224 ( ), Virginia Commonwealth University Reanimation Engineering Science Center (VCURES), Richmond, Virginia 23298 ( ), Massey Cancer Center, Virginia Commonwealth University, Richmond VA, 23298 ( and Virginia Commonwealth University, Dept. of Biochemistry and Molecular Biology, Richmond VA, 23298 ( ).

PMID: 24818173
PMCID: PMC4012677

Abstract

While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.

Keywords: Breast Cancer; ErbB2; Estrogen receptor; Resistance; Triple negative.

Abstract

Grants and funding